당뇨병용 의료기기 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 유통 채널별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Diabetes Devices Market Summary

The global diabetes devices market sizewas estimated at USD 45.85 billion in 2025 and is projected to reach USD 101.66 billion by 2033, growing at a CAGR of 10.5% from 2026 to 2033. The market is primarily driven by growing prevalence of diabetes, advanced technology, the growing usage of insulin delivery devices, and the rise in obesity rates.

Major manufacturers are concentrating on technological innovation and the creation of advanced products to secure a significant portion of the diabetes care devices market. For instance, in January 2025, Dexcom announced the expansion of its AI-enabled continuous glucose monitoring ecosystem through new integrations with digital health and automated insulin delivery platforms to improve personalized diabetes management and remote patient monitoring capabilities. The development strengthened the company's connected diabetes care portfolio and is expected to accelerate the adoption of advanced CGM and automated insulin delivery technologies globally, thereby supporting the diabetes management devices market growth.

The increasing prevalence of diabetes worldwide has created a strong demand for diabetes devices over the forecast period. According to the latest 11th Edition of the International Diabetes Federation (IDF) Diabetes Atlas published in 2025, approximately 589 million adults aged 20-79 years are currently living with diabetes globally, representing nearly 1 in 9 adults worldwide. The organization further projects that the number of adults living with diabetes likely to increase to nearly 853 million by 2050, reflecting the rapidly growing global disease burden. In addition, more than 40% of diabetic individuals remain undiagnosed, increasing the risk of severe complications and driving the need for continuous glucose monitoring systems, insulin delivery devices, and early diagnostic technologies. Furthermore, over 81% of people with diabetes live in low- and middle-income countries, highlighting significant growth opportunities for affordable and connected diabetes care solutions across emerging markets. These rising prevalence trends, coupled with increasing obesity rates, sedentary lifestyles, and aging populations, are expected to significantly support the growth of the diabetes devices market during the forecast period.

The increasing demand in the diabetes care drugs devices market is largely driven by the growing need to reduce diabetes-related complications, prevent prolonged hospital stays, and lower mortality rates among diabetic patients. Diabetes devices such as continuous glucose monitors, insulin delivery systems, and blood glucose monitoring devices enable real-time tracking and effective management of blood sugar levels, helping patients take timely action to control their condition. These technologies support better treatment adherence and allow healthcare providers to make faster adjustments to therapy plans, resulting in improved disease management and patient outcomes. In addition, the rising adoption of advanced diabetes care solutions is improving the overall quality of life for individuals living with diabetes by minimizing the risk of severe health complications. Consequently, the expanding use of these devices continues to strengthen the growth of the diabetes care drugs devices market by enhancing patient care, improving clinical efficiency, and supporting long-term disease management.

The market is growing due to the increasing prevalence of diabetes resulting from aging, obesity, and unhealthy lifestyle choices. Obesity is a significant factor leading to diabetes. According to the latest data published by the World Health Organization in 2025, more than 2.5 billion adults aged 18 years and older were overweight in 2022, including over 890 million adults living with obesity. In addition, the worldwide prevalence of obesity has more than doubled since 1990, with approximately 16% of the global adult population classified as obese. Furthermore, the World Obesity Federation reported in its 2025 World Obesity Atlas that the number of adults living with obesity is projected to increase nearly 1.53 billion by 2035. Rising obesity levels are significantly increasing the risk of Type 2 diabetes, cardiovascular diseases, and metabolic disorders, thereby driving the demand for continuous glucose monitoring systems, insulin delivery devices, and other advanced diabetes management technologies during the forecast period.

The presence of a substantial elderly population, affordable healthcare options, cost-effective labor, and less rigorous regulatory frameworks are driving diabetic device manufacturers to expand. They are prioritizing exploiting opportunities in emerging markets to increase their market dominance. The demand for diabetes devices is also rising due to technological advancements, including introducing of advanced insulin pumps and pens. Significant companies are concentrating on technological advancements and creating advanced products to secure a significant portion of the market. For instance, in April 2025, Medtronic announced the U.S. FDA submission for its interoperable MiniMed 780G insulin pump designed for integration with Abbott's advanced CGM platform. The development is expected to accelerate the adoption of connected diabetes management ecosystems by improving interoperability, enhancing glucose control automation, and expanding access to advanced insulin delivery technologies across global markets.

Global Diabetes Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the global diabetes devices market report based on type, distribution channel, end-use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• BGM Devices
  • Self-Monitoring Devices
  • Blood Glucose Meters
  • Testing Strips
  • Lancets
  • Continuous Glucose Monitoring Devices
  • Sensors
  • Transmitters
  • Receiver
• Insulin Delivery Devices
  • Pens
  • Pum
  • Syringes
  • Jet Injectors
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital pharmacies
• Retail Pharmacies
• Diabetes Clinics/Centers
• Online Pharmacies
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Centers
• Homecare
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Distribution Channel
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Distribution Channel outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Diabetes Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Diabetes Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Diabetes Devices Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Diabetes Devices Market: Type Movement Analysis
• 4.3. Diabetes Devices Market by Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. BGM Devices
  • 4.5.1. BGM Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Self Monitoring Devices
    • 4.5.2.1. Self Monitoring Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.2. Blood Glucose Meter
      • 4.5.2.2.1. Blood Glucose Meter Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.3. Testing Strips
      • 4.5.2.3.1. Testing Strips Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.4. Lancets
      • 4.5.2.4.1. Lancets Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Continuous Glucose Monitoring Devices
    • 4.5.3.1. Continous Glucose Monitoring Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.2. Sensors
      • 4.5.3.2.1. Sensors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.3. Transmitter
      • 4.5.3.3.1. Transmitters Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.4. Receiver
      • 4.5.3.4.1. Receivers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Insulin Delivery Devices
  • 4.6.1. Insulin Delivery Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Pens
    • 4.6.2.1. Pens Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Pumps
    • 4.6.3.1. Pumps Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Syringes
    • 4.6.4.1. Syringes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.5. Jet Injector
    • 4.6.5.1. Jet Injector Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Diabetes Devices Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Diabetes Devices Market: Distribution Channel Movement Analysis
• 5.3. Diabetes Devices Market by Distribution Channel Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Hospital Pharmacies
  • 5.5.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Retail Pharmacies
  • 5.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Diabetes Clinics/ Centers
  • 5.7.1. Diabetes Clinics/ Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Online Pharmacies
  • 5.8.1. Online PharmaciesMarket Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Diabetes Devices Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Diabetes Devices Market: End Use Movement Analysis
• 6.3. Diabetes Devices Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Dignostic Centers
  • 6.6.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Homecare
  • 6.7.1. Homecare Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Diabetes Devices Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Diabetes Devices Market Movement Analysis
• 7.3. Diabetes Devices Market: Regional Estimates & Trend Analysis by Type & Distribution Channel
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. North America
  • 7.5.1. North America Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Europe
  • 7.5.5. Europe Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. UK
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. UK Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Germany
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. Germany Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. France
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement scenario
    • 7.5.8.5. France Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Italy
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement scenario
    • 7.5.9.5. Italy Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.10. Spain
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Competitive Scenario
    • 7.5.10.3. Regulatory Framework
    • 7.5.10.4. Reimbursement scenario
    • 7.5.10.5. Spain Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.11. Denmark
    • 7.5.11.1. Key Country Dynamics
    • 7.5.11.2. Competitive Scenario
    • 7.5.11.3. Regulatory Framework
    • 7.5.11.4. Reimbursement scenario
    • 7.5.11.5. Denmark Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.12. Sweden
    • 7.5.12.1. Key Country Dynamics
    • 7.5.12.2. Competitive Scenario
    • 7.5.12.3. Regulatory Framework
    • 7.5.12.4. Reimbursement scenario
    • 7.5.12.5. Sweden Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.13. Norway
    • 7.5.13.1. Key Country Dynamics
    • 7.5.13.2. Competitive Scenario
    • 7.5.13.3. Regulatory Framework
    • 7.5.13.4. Reimbursement scenario
    • 7.5.13.5. Norway Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Japan Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. China Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. India Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. South Korea Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Australia Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Thailand Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Brazil Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Mexico
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Mexico Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. Argentina
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Argentina Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. South Africa Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Saudi Arabia Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. UAE Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. Kuwait Diabetes Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. Medtronic plc
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Abbott Laboratories
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. F.Hoffmann-La-Ltd.
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Bayer AG
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Lifescan, Inc.
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. B Braun Melsungen AG
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Lifescan, Inc.
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. Dexcom Inc.
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. Insulet Corporation
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Product Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Ypsomed Holdings
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Product Benchmarking
    • 8.2.10.4. Strategic Initiatives
  • 8.2.11. Companion Medical
    • 8.2.11.1. Company Overview
    • 8.2.11.2. Financial Performance
    • 8.2.11.3. Product Benchmarking
    • 8.2.11.4. Strategic Initiatives
  • 8.2.12. Sanofi
    • 8.2.12.1. Company Overview
    • 8.2.12.2. Financial Performance
    • 8.2.12.3. Product Benchmarking
    • 8.2.12.4. Strategic Initiatives
  • 8.2.13. Valeritas Holding Inc.
    • 8.2.13.1. Company Overview
    • 8.2.13.2. Financial Performance
    • 8.2.13.3. Product Benchmarking
    • 8.2.13.4. Strategic Initiatives
  • 8.2.14. Novo Nordisk
    • 8.2.14.1. Company Overview
    • 8.2.14.2. Financial Performance
    • 8.2.14.3. Product Benchmarking
    • 8.2.14.4. Strategic Initiatives
  • 8.2.15. Arkray, Inc.
    • 8.2.15.1. Company Overview
    • 8.2.15.2. Financial Performance
    • 8.2.15.3. Product Benchmarking
    • 8.2.15.4. Strategic Initiatives